140 related articles for article (PubMed ID: 19574209)
1. Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD).
Sánchez Henarejos P; Ros Martínez S; Marín Zafra GR; Alonso Romero JL; Navarrete Montoya A
Clin Transl Oncol; 2009 Jul; 11(7):486-7. PubMed ID: 19574209
[TBL] [Abstract][Full Text] [Related]
2. An intertrigo-like eruption from pegylated liposomal doxorubicin.
Korver GE; Ronald H; Petersen MJ
J Drugs Dermatol; 2006 Oct; 5(9):901-2. PubMed ID: 17039658
[TBL] [Abstract][Full Text] [Related]
3. Case of severe bullous erythema including intertrigo-like eruptions with angioedema induced by pegylated liposomal doxorubicin.
Totsuka M; Watanabe Y; Asai C; Takahashi S; Ishikawa H; Takamura N; Hagiwara M; Aihara M
J Dermatol; 2019 Jun; 46(6):535-539. PubMed ID: 31021010
[TBL] [Abstract][Full Text] [Related]
4. Intertrigo-like dermatitis with pegylated liposomal doxorubicin: diagnosis and management.
Najem A; Deregnaucourt D; Ramdane S; Dridba M; Djouba F; Vercambre-Darras S
J Clin Oncol; 2014 Nov; 32(31):e104-6. PubMed ID: 24550424
[No Abstract] [Full Text] [Related]
5. Striking follicular eruption to pegylated liposomal doxorubicin.
Dai J; Micheletti R; Rosenbach M; Chu EY
Am J Dermatopathol; 2014 Jul; 36(7):590-1. PubMed ID: 24614205
[TBL] [Abstract][Full Text] [Related]
6. Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single-institution, retrospective case series.
Vaccaro M; Santarpia M; Calapai G; Mannucci C; Borgia F; Altavilla G; Cannavò SP
Br J Dermatol; 2017 Feb; 176(2):507-509. PubMed ID: 27291307
[No Abstract] [Full Text] [Related]
7. Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
English JC; Toney R; Patterson JW
J Cutan Pathol; 2003 Oct; 30(9):591-5. PubMed ID: 14507411
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.
Yao J; Pan S; Fan X; Jiang X; Yang Y; Jin J; Liu Y
J Chemother; 2020 Jul; 32(4):202-207. PubMed ID: 32281493
[TBL] [Abstract][Full Text] [Related]
9. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
[TBL] [Abstract][Full Text] [Related]
10. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.
Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M
Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192
[TBL] [Abstract][Full Text] [Related]
11. Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
Lu YC; Ou-Yang FU; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
In Vivo; 2016; 30(2):159-63. PubMed ID: 26912829
[TBL] [Abstract][Full Text] [Related]
12. "Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome".
Von Moos R; Cathomas R
Eur J Dermatol; 2009; 19(3):264-5. PubMed ID: 19213658
[No Abstract] [Full Text] [Related]
13. What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?
Grenader T; Gabizon A
J Clin Oncol; 2010 Apr; 28(12):e193-4; author reply e195-6. PubMed ID: 20194839
[No Abstract] [Full Text] [Related]
14. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report.
Munzone E; Di Pietro A; Goldhirsch A; Minchella I; Verri E; Cossu Rocca M; Marenghi C; Curigliano G; Radice D; Adamoli L; Nolè F
Breast; 2010 Feb; 19(1):33-7. PubMed ID: 19884008
[TBL] [Abstract][Full Text] [Related]
15. Severe palmoplantar erythrodysesthesia and intertrigolike eruption induced by polyethylene glycol-coated liposomal doxorubicin.
Campanelli A; Kerl K; Lübbe J
J Eur Acad Dermatol Venereol; 2006 Sep; 20(8):1022-4. PubMed ID: 16922969
[No Abstract] [Full Text] [Related]
16. Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review.
Savani M; Woerner K; Bu L; Birkenbach M; Skubitz KM
Cancer Chemother Pharmacol; 2021 Feb; 87(2):289-294. PubMed ID: 33388949
[TBL] [Abstract][Full Text] [Related]
17. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
[TBL] [Abstract][Full Text] [Related]
18. Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).
Eckes J; Schmah O; Siebers JW; Groh U; Zschiedrich S; Rautenberg B; Hasenburg A; Jansen M; Hug MJ; Winkler K; Pütz G
BMC Cancer; 2011 Aug; 11():337. PubMed ID: 21816044
[TBL] [Abstract][Full Text] [Related]
19. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
20. Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment.
Carron PL; Padilla M; Maurizi Balzan J
Hemodial Int; 2014 Oct; 18(4):846-7. PubMed ID: 25040096
[No Abstract] [Full Text] [Related]
[Next] [New Search]
